N-Acetyl Cystein and Contrast Nephropathy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 549 participants.

Also called NCT01820195

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 549 participants (planned count) (from the registry)
Sponsor
Imam Khomeini Hospital (from the registry)
Registry
  • NCT NCT01820195
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Iran (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01820195. Randomized; double masking; primary purpose prevention. Start 2013-03 (registry gives no type); primary completion 2014-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
N-Acetyl Cystein and Contrast Nephropathy
Condition
Chronic Kidney Disease Stage 2
Condition
Radiographic Contrast Agent Nephropathy
Intervention (Drug)
Oral N-Acetyl Cystein
Intervention (Drug)
IV N-Acetyl Cystein
Intervention (Drug)
Placebo group
Lead sponsor
Imam Khomeini Hospital (class: other)
Collaborator
Tehran Heart Center (class: other)

Record details

Record id
cardio:ct-nct01820195
Content hash
6aed5c4d2118c25461a88ebf90e096f74ed8351b4be05857af5710e8e20613cd